{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-028368","form_type":"8-K","ticker":"ANGO","cik":"0001275187","company_name":"ANGIODYNAMICS INC","filed_at":"2026-07-14T11:30:53+00:00","discovered_at":"2026-07-14T11:35:00.305556+00:00","generated_at":"2026-07-14T11:35:12.840605+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%","bullets":["Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).","Full year pro forma net sales $320.2M (+9.4%); GAAP net loss $36.7M ($0.88 loss per share); adjusted EBITDA $13.2M.","FY2027 guidance: net sales $336M-$341M, Med Tech growth 12-15%, adjusted EBITDA $13M-$16M, adjusted EPS ($0.29)-($0.24).","Clinical milestones: FDA IDE approvals for APEX-Return, PAVE, RELIEF studies; Palmetto GBA LCD for NanoKnife IRE in prostate/liver cancer.","Ended FY2026 with $53.9M cash, debt-free; tariff headwinds $4.8M in FY2026, expected similar in FY2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-028368","json":"https://secwatch.observer/filing/0001140361-26-028368.json","markdown":"https://secwatch.observer/filing/0001140361-26-028368.md","text":"https://secwatch.observer/filing/0001140361-26-028368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/0001140361-26-028368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/ef20077916_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T11:35:12.840605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}